

16 April 2020

Statement from Dick Elsy, the High Value Manufacturing Catapult's CEO:

“I’m very pleased to confirm that we have now secured MHRA approval for the Penlon Prima ESO2 device which has been undergoing stringent testing and clinical trials for the last two weeks. Ventilators of this type are complex and critical pieces of medical equipment so ensuring the absolute adherence to regulatory standards and meeting clinical needs were always our priorities. We will now accelerate the ramp up of production at the Penlon site in Oxfordshire and the new VCUK production lines we’ve built in Broughton, Dagenham and Woking. Having already commenced deliveries of the Smiths Group’s paraPAC plus devices, we are working closely with our supply chain partners to rapidly scale up production to achieve our target of at least 1,500 units a week of the combined Penlon and Smiths models. I want to take this opportunity to again thank every member of the consortium and the hundreds of dedicated colleagues who have been working day and night to get us to this point.”